Integrating Circulating-free DNA (cfDNA) Analysis into Clinical Practice: Opportunities and Challenges

Overview

Journal Br J Cancer

Specialty Oncology

Date 2022 Mar 29

PMID 35347327

Authors

Miguel Garcia-Pardo

Maisam Makarem

Janice J N Li

Deirdre Kelly

Natasha B Leighl

Affiliations

Soon will be listed here.

Abstract

In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of circulating tumour DNA (ctDNA) have enabled the integration of liquid biopsy into clinical practice for molecular profiling. ctDNA has also emerged as a promising biomarker for prognostication, monitoring disease response, detection of minimal residual disease and early diagnosis. In this Review, we discuss current and future clinical applications of ctDNA primarily in non-small cell lung cancer in addition to other solid tumours.

Citing Articles

Radiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors.

Khanyile R, Chipiti T, Hull R, Dlamini Z Cancers (Basel). 2025; 17(5).

PMID: 40075655 PMC: 11899325. DOI: 10.3390/cancers17050808.

Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.

Cao P, Jia X, Wang X, Fan L, Chen Z, Zhao Y BMC Cancer. 2025; 25(1):443.

PMID: 40075375 PMC: 11899356. DOI: 10.1186/s12885-025-13823-8.

"Plasma-first" approach for molecular genotyping in non-small cell lung cancer: A narrative review.

Garcia-Pardo M, Leighl N J Liq Biopsy. 2025; 2:100123.

PMID: 40028483 PMC: 11863935. DOI: 10.1016/j.jlb.2023.100123.

Moving liquid biopsies to the Front-line of lung cancer treatment decisions.

Raez L, Carracedo C, Rosas D, Alvarez A J Liq Biopsy. 2025; 1:100006.

PMID: 40027286 PMC: 11863809. DOI: 10.1016/j.jlb.2023.100006.

Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Leite da Silva L, Saldanha E, de Menezes J, Halamy Pereira L, de Braganca Dos Santos J, Buonopane I Oncologist. 2025; 30(2).

PMID: 39998904 PMC: 11853598. DOI: 10.1093/oncolo/oyae344.

References

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

Leighl N, Page R, Raymond V, Daniel D, Divers S, Reckamp K . Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019; 25(15):4691-4700. DOI: 10.1158/1078-0432.CCR-19-0624. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Raman L, Van der Linden M, Van der Eecken K, Vermaelen K, Demedts I, Surmont V . Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. Genome Med. 2020; 12(1):35. PMC: 7175544. DOI: 10.1186/s13073-020-00735-4. View

Rolfo C, Cardona A, Cristofanilli M, Paz-Ares L, Diaz Mochon J, Duran I . Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020; 151:102978. DOI: 10.1016/j.critrevonc.2020.102978. View

Park C, Cho H, Choi Y, Oh I, Kim Y . A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Cancer Res Treat. 2018; 51(2):777-787. PMC: 6473264. DOI: 10.4143/crt.2018.387. View

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F . Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020; 39(1):95. PMC: 7254767. DOI: 10.1186/s13046-020-01601-2. View

Kato S, Okamura R, Baumgartner J, Patel H, Leichman L, Kelly K . Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018; 24(24):6248-6256. PMC: 6384095. DOI: 10.1158/1078-0432.CCR-18-1128. View

10.

Jenkins S, Yang J, Ramalingam S, Yu K, Patel S, Weston S . Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 12(7):1061-1070. DOI: 10.1016/j.jtho.2017.04.003. View

11.

Salvianti F, Gelmini S, Mancini I, Pazzagli M, Pillozzi S, Giommoni E . Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. Br J Cancer. 2021; 125(1):94-100. PMC: 8257609. DOI: 10.1038/s41416-021-01399-6. View

12.

Willis J, Lefterova M, Artyomenko A, Kasi P, Nakamura Y, Mody K . Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res. 2019; 25(23):7035-7045. DOI: 10.1158/1078-0432.CCR-19-1324. View

13.

Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E . Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. J Thorac Oncol. 2019; 15(3):383-391. DOI: 10.1016/j.jtho.2019.11.024. View

14.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

15.

Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehm T . Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Ann Oncol. 2018; 29(8):1777-1783. DOI: 10.1093/annonc/mdy211. View

16.

Liu H, Vuppalapaty M, Wilkerson C, Renier C, Chiu M, Lemaire C . Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. Front Oncol. 2020; 10:572895. PMC: 7578230. DOI: 10.3389/fonc.2020.572895. View

17.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

18.

Sonpavde G, Agarwal N, Pond G, Nagy R, Nussenzveig R, Hahn A . Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019; 125(9):1459-1469. DOI: 10.1002/cncr.31959. View

19.

Maron S, Chase L, Lomnicki S, Kochanny S, Moore K, Joshi S . Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res. 2019; 25(23):7098-7112. PMC: 6891164. DOI: 10.1158/1078-0432.CCR-19-1704. View

20.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View